Elizabeth Jungman

Elizabeth Jungman

  • Director
  • Public Health,
  • The Pew Charitable Trusts


Elizabeth Jungman directs Pew’s work on public health, overseeing initiatives related to antibiotics and innovation and the safety of prescription drugs, over-the-counter medicines, and other consumer health care products.

Before joining Pew, she served as a senior health policy adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions, where she played a key role in drafting and negotiating the Food and Drug Administration Safety and Innovation Act of 2012, the FDA provisions in the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013, and the Drug Quality and Security Act of 2013, which included drug compounding and supply chain security measures.

Before moving to the Hill, Jungman was in private legal practice, counseling clients on a broad range of FDA regulatory matters and other health care issues related to the human pharmaceutical industry. She serves on FDA’s Pharmacy Compounding Advisory Committee. She has an undergraduate biology degree from Harvard College, a Juris Doctor from Georgetown University, and a master’s degree in public health from Johns Hopkins University.

Recent Work

View All
  • Quality Standards for Stock Supplies of Compounded Drugs Keep Patients Safe

    Medical providers may at times treat patients whose needs cannot be met by commercially available, Food and Drug Administration-approved products, such as a child who requires a liquid form of a medicine approved only as a pill. In these situations, providers can instead prescribe compounded drugs, which are made by pharmacists or physicians instead of drug manufacturers. To protect patient... Read More

  • State Oversight of Drug Compounding

    More than five years have passed since contaminated injections compounded at a single pharmacy caused 76 deaths and 778 illnesses in a nationwide outbreak of fungal meningitis, a tragedy that made clear that the complex, technical practice of drug compounding was not subject to a level of oversight appropriate to its potential risks to patients. Since then, state and federal officials have been... Read More

  • Report: Majority of States Have Adopted Policies to Make Compounded Drugs Safer

    According to “State Oversight of Drug Compounding,” a report released today by The Pew Charitable Trusts and the National Association of Boards of Pharmacy (NABP), states have taken important steps to protect patient safety since Pew research first assessed their compounding policies in 2015. Read More

Media Contact

Laurie Boeder

Director, Communications